Key Takeaways IONS posted Q2 EPS of $0.86 and revenue of$452M, both beating estimates and doubling year over year.Tryngolza and Wainua drove a 43% rise in commercial revenues, reaching $103M for the quarter.IONS raised its 2025 revenue outlook to$825-$850M, citing strong Tryngolza uptake and market expansion plans.Ionis Pharmaceuticals (IONS) reported second-quarter 2025 adjusted earnings per share (EPS) of 86 cents, significantly beating the Zacks Consensus Estimate of 27 cents. In the year-ago period, t ...